OncoRNA develops personalized mRNA-based cancer vaccines that target the unique genetic profiles of tumors by producing over 100 neoantigens in just three weeks using synthetic DNA pool technology. This approach addresses the limitations of traditional off-the-shelf cancer therapies, providing a tailored immune response to enhance the effectiveness of cancer treatment.
Funding
Funding not disclosed
Founders
Product
Problem
Current off-the-shelf cancer therapies are insufficient for many patients, necessitating personalized treatment approaches. Traditional methods for producing personalized cancer vaccines are often slow and expensive, limiting accessibility and timely treatment.
Solution
OncoRNA develops personalized mRNA-based cancer vaccines that target the unique genetic profiles of individual tumors. Their technology utilizes a synthetic DNA pool to produce over 100 neoantigens in approximately three weeks. This approach aims to provide a tailored immune response, enhancing the precision and effectiveness of cancer treatment by empowering the immune system to recognize and attack cancer cells. The entire process takes place in a single tube to deliver a GMP-grade cancer personalized immunotherapy batch with all the treatment doses.
Target Audience
The primary target audience includes cancer patients who require personalized treatment options and healthcare providers specializing in oncology and immunotherapy.
Features
- snmRNA pool technology enabling the production of mRNA-based vaccines.
- Rapid production process, delivering personalized vaccines in approximately 3 weeks.
- Ability to produce over 100 neoantigens, providing a broad and tailored immune response.
- Individualized RNA production, ensuring higher homogeneity in yield of RNA production and in-vivo translation.
- GMP-grade manufacturing process.